WGS vs. PRVA, USPH, PNTG, INNV, TALK, DCGO, SHCR, PIII, EUDA, and ATPC
Should you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Privia Health Group (PRVA), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), EUDA Health (EUDA), and Agape ATP (ATPC). These companies are all part of the "health services" industry.
Privia Health Group (NASDAQ:PRVA) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Privia Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.
Privia Health Group has a net margin of 1.11% compared to Privia Health Group's net margin of -60.86%. GeneDx's return on equity of 3.13% beat Privia Health Group's return on equity.
Privia Health Group presently has a consensus target price of $25.08, suggesting a potential upside of 46.26%. GeneDx has a consensus target price of $18.00, suggesting a potential downside of 13.83%. Given GeneDx's stronger consensus rating and higher probable upside, analysts clearly believe Privia Health Group is more favorable than GeneDx.
94.5% of Privia Health Group shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 14.2% of Privia Health Group shares are owned by company insiders. Comparatively, 28.1% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Privia Health Group has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
Privia Health Group received 52 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 72.37% of users gave Privia Health Group an outperform vote while only 42.86% of users gave GeneDx an outperform vote.
In the previous week, Privia Health Group had 11 more articles in the media than GeneDx. MarketBeat recorded 14 mentions for Privia Health Group and 3 mentions for GeneDx. Privia Health Group's average media sentiment score of 0.93 beat GeneDx's score of 0.90 indicating that GeneDx is being referred to more favorably in the news media.
Summary
Privia Health Group beats GeneDx on 14 of the 18 factors compared between the two stocks.
Get GeneDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
